John H Eldridge
Overview
Explore the profile of John H Eldridge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matassov D, DeWald L, Hamm S, Nowak R, Gerardi C, Latham T, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39203984
There are currently no prophylactic vaccines licensed to protect against Lassa fever caused by Lassa virus (LASV) infection. The Emergent BioSolutions (EBS) vaccine candidate, EBS-LASV, is being developed for the...
2.
Woolsey C, Borisevich V, Agans K, OToole R, Fenton K, Harrison M, et al.
J Infect Dis
. 2023 May;
228(Suppl 7):S660-S670.
PMID: 37171813
Background: The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and...
3.
Woolsey C, Cross R, Agans K, Borisevich V, Deer D, Geisbert J, et al.
PLoS Negl Trop Dis
. 2022 May;
16(5):e0010433.
PMID: 35622847
Background: Marburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as demonstrated by its high associated mortality rate (23-90%) and recent emergence in West Africa for...
4.
Eldridge J, Egan M, Matassov D, Hamm S, Hermida L, Chen T, et al.
Vaccine
. 2021 Aug;
39(38):5436-5441.
PMID: 34373117
Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum phosphate. This...
5.
Woolsey C, Jankeel A, Matassov D, Geisbert J, Agans K, Borisevich V, et al.
Sci Rep
. 2020 Feb;
10(1):3071.
PMID: 32080323
Postexposure immunization can prevent disease and reduce transmission following pathogen exposure. The rapid immunostimulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make them suitable postexposure treatments against the filoviruses...
6.
Clarke D, Xu R, Matassov D, Latham T, Ota-Setlik A, Gerardi C, et al.
Lancet Infect Dis
. 2020 Jan;
20(4):455-466.
PMID: 31952923
Background: The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing...
7.
Cross R, Xu R, Matassov D, Hamm S, Latham T, Gerardi C, et al.
J Clin Invest
. 2019 Dec;
130(1):539-551.
PMID: 31820871
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of...
8.
Elizaga M, Li S, Kochar N, Wilson G, Allen M, Tieu H, et al.
PLoS One
. 2018 Sep;
13(9):e0202753.
PMID: 30235286
Background: The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study...
9.
Suksanpaisan L, Xu R, Tesfay M, Bomidi C, Hamm S, Vandergaast R, et al.
Mol Ther Oncolytics
. 2018 Jul;
10:1-13.
PMID: 29998190
Immunotherapy for HPV malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including...
10.
Woolsey C, Geisbert J, Matassov D, Agans K, Borisevich V, Cross R, et al.
J Infect Dis
. 2018 Jun;
218(suppl_5):S582-S587.
PMID: 29939296
A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV...